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Objectives: While Caucasian women are more likely to be diagnosed with endometrial 
cancer compared to African-American women, the rate of mortality is higher for African 
Americans. The cause of this disparity is unknown. We analyzed the time interval from 
diagnosis of endometrial cancer to treatment as it pertains to race and socioeconomic 
factors and its possible impact on survival.
Methods: This was a retrospective, single institution chart review using a cancer registry 
database. We identified 889 patients who were diagnosed with endometrial cancer 
between January 2005 and June 2012. Clinicopathologic characteristics, demograph-
ics, insurance status, distance from medical center, body mass index (BMI), dates of 
diagnosis, and treatment were obtained from the medical records. Survival and associ-
ation was determined by a one-way ANOVA test.
results: At the time of the study, 699 patients were alive and 190 dead. The average 
age was noted to be 62 years (24–91 years). Stages I–IV disease accounted for 69, 
6, 15, and 10%, respectively. White race accounted for 64%, African Americans 24%, 
and Hispanics 7% of our study population. Majority of patients were privately insured 
(n =  441) followed by Medicare (n =  375). The mean interval time from diagnosis to 
treatment was 47.5 days (0–363). A statistically significant difference was noted for this 
time interval with regard to both race and insurance status: white and African Americans 
(42.6 vs. 57.3 days, p = 0.048), privately insured and Medicare (38.4 vs. 54.1 days, 
p < 0.001). There was a significant association with increased risk of death with a longer 
delay (43.3 vs. 64.8 days, p < 0.001). No statistically significance was noted for distance 
from medical center or BMI.
conclusion: A significant increase in interval of time from diagnosis to treatment of 
endometrial cancer was seen in both race and insurance status. A longer interval from 
diagnosis to treatment was associated mortality. The causes of these delays are likely 
multifactorial but deem further investigation given these data.
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inTrODUcTiOn
According to National Cancer Institute Surveillance Epidemiology 
and End Results (SEER), it is estimated that 49,560 women were 
diagnosed and 8,190 women died from cancer of the uterus 
in 2013 (1). Endometrial cancer, which accounts for 95% of 
cancer of the uterine corpus, is the most common gynecologic 
malignancy (2). Racial differences in the incidence and mortality 
of endometrial cancer have been noted with higher incidence 
in Caucasian women compared to African-American women; 
however, the mortality rate is 85% higher for African-American 
women (1). The cause of this disparity in mortality rates among 
Caucasian women and African-American women is thought to be 
multifactorial. Some studies have shown that African-American 
women present with poor prognostic features, such as higher 
grade tumors (Grades II and III), advanced stage (Stages III or 
IV), and non-endometrioid (Type II) endometrial cancers (3). 
In one study by Setiawan et al., African Americans and Latinas 
had higher proportions of high-grade tumors (32.7 and 29.5%, 
respectively) compared to whites (19.2%) as well as more aggres-
sive histology among African Americans (30.9%) and Latinas 
(26.2%) compared to whites (8.7%) (4). Other authors have 
suggested that the type of initial treatment offered to African-
American women may have increased the mortality rate with 
Caucasian women being more likely than African Americans 
to receive surgery and radiation therapy (5). Another possible 
explanation is that the molecular phenotypes of endometrial 
cancers that arise in African-American women tend to have a 
higher rate of TP53 inactivation and decreased expression of 
PTEN (6). p53 tumor suppressor gene inactivation has been 
associated with more adverse histologies and advanced-stage 
disease, while PTEN mutation, the most frequent molecular 
alteration observed in endometrial cancer, is associated with a 
more favorable outcome (6).
Few studies have explored interval between diagnosis of 
endometrial cancer and the time of treatment. Minority races 
have been associated with lower socioeconomic status that may 
limit access to care. The objective of this study is to examine the 
interval from diagnosis to treatment in relation to race, socioeco-
nomic status, and payor status at a single tertiary care institution.
MaTerials anD MeThODs
Using the Cancer Registry at Rush University Medical Center, 
we performed a retrospective chart review of patients diagnosed 
with and/or treated for endometrial cancer from January 1, 2005 
to June 1, 2012. The Rush University Medical Center Internal 
Review Board approved this study. Patients were selected if 
they were diagnosed with primary cancer involving the uterus 
and were initially diagnosed and/or treated within the Rush 
University Medical Center network. Of note, all patients were 
treated by an attending gynecologic oncologist; there is no house 
staff clinic present at this institution. Patients whose primary 
tumor was outside the uterine corpus, who were diagnosed 
with primary cervical cancer or with uterine sarcomas, were 
excluded. The following information was extracted from patient 
charts: age at initial diagnosis, race/ethnicity, body mass index 
(BMI), insurance status, zip code, date of initial diagnosis, date 
of initial treatment, type of initial treatment (either surgical, 
radiation therapy, or chemotherapy), stage, histological type, and 
vital status (dead or alive) at the time of data collection. Time of 
diagnosis was determined from the date a pathological specimen 
was collected (day 0) either by endometrial sampling or from the 
initial surgery for a non-malignant cause (18.3%). For 20 cases, 
no treatment date was available and these patients were excluded 
from further analysis in this study. Date of treatment was deter-
mined using the date of patient’s surgical staging procedure or for 
patients who did not undergo surgery the initial date of radiation/
chemotherapy treatment; for patients who underwent a hysterec-
tomy for another cause (prior to diagnosis of endometrial cancer), 
the date of their hysterectomy was used. The interval treatment 
time was determined by the number of days between the dates of 
diagnosis and treatment. Distance from Rush University Medical 
Center was determined using patients’ listed home zip code and 
calculating the distance from that zip code against that of the 
medical center, this calculation was performed in the standard 
fashion. Analysis of the data was performed using the analytical 
software SPSS statistics 21.0; chi square test was used to analysis 
stage and vital status. For analysis of race and insurance status 
on treatment delay, we performed ANOVA. To see the relation-
ship of BMI and distance from treatment center and its impact 
on delay in treatment time, we performed a regression analysis. 
A multivariate analysis was also performed.
resUlTs
A total of 964 charts were reviewed for this study. Seventy-five 
charts did not meet inclusion criteria leaving a total of 889 charts 
for analysis. Demographic information is outlined in Table  1. 
Average age of all patients was 62 years old (range 24–91 years). 
Of the cases reviewed, 64.3% were white, 24.3% were African-
American, 7.0% were Hispanic, 0.7% Asian, and 3.6% were of 
other or unknown race. In terms of stage of disease at time of 
diagnoses, Stage I disease accounted for 68.8% (612/889), Stage 
II 6.4% (57/889), Stage III 14.5% (129/889), and Stage IV 10.1% 
(90/889); one patient stage was unknown. The majority of the 
histologic types were grades 1 and 2 endometrioid adenocarci-
noma, 31.6% (281/889) and 30.3% (271/889), respectively. Poorly 
differentiated cancers made up 26.1% (232/889) including a 
combination of grade 3 endometrioid adenocarcinoma, serous, 
carcinosarcoma, and leiomyosarcoma. The remaining histologic 
group was defined in the registry as “cell type not determined” 
(11.8%). Majority of patients, 49.6% (441/889), had private 
insurance, followed closely by Medicare 42.1% (374/889) and 
Medicaid 4.4% (39/889). Average distance from health center 
was noted to be 23.5 miles (range 0–1,022 miles); for one patient, 
no information on zip code was available and thus unable to 
calculate distance. Average BMI of patients in study was 35 kg/
m2; however, information was missing for 145 (16%) patients. 
At the time of data collection, 699 (78.6%) patients were alive 
and 190 (21.4%) were dead. As it would be expected, vital status 
varied between stages with majority of Stage I patient being alive 
at the time of analysis of this study. For stage I disease, 89.9% 
(550) patients were alive vs. 73.7% for stage II, 59.7% for stage 
TaBle 3 | Mean treatment time in relation to insurance per stage.
insurance stage i stage ii stage iii stage iV
Mean treatment interval (days)
Private 39.0 50.8 34.4 37.3
Medicaid 53.1 275.0 40.4 179.0
Medicare 53.6 65.4 48.3 38.9
Other/unknown 109.0 46.0 40.0 3.5
Total 46.4 66.3 42.8 47.0
p = 0.01 p = 0.06 p = 0.489 p = 0.03
TaBle 2 | Mean treatment time (days) in relationship to race, insurance 
status, and vital status.
Demographics Mean treatment time (days) p value
race
White 42.6 p = 0.048
African-American 57.3
Hispanic 58.2
Asian 28.6
Other 54
Total 47.6
insurance
Private 38.4 p < 0.001
Medicaid 78.1
Medicare 54.1
Self-pay 53.5
Other/unknown 63.6
Total 47.9
Vital status
Alive 43.3 p < 0.001
Dead 64.8
Total 47.9
TaBle 1 | Demographic of patients.
Demographics number of patients
race
White 572 (64.3%)
African-American 216 (24.3%)
Hispanic 62 (7%)
Asian 7 (0.7%)
Other/unknown 32 (3.6%)
stage of disease
Stage I 612 (68.8%)
Stage II 57 (6.4%)
Stage III 129 (14.5%)
Stage IV 90 (10.1%)
Stage unknown 1 (0.1%)
insurance
Private 441 (49/6%)
Medicaid 39 (4.4%)
Medicare 374 (42.1%)
Self-pay 16 (1.8%)
Other/unknown 18 (2%)
Body mass index
Mean 34.6 mg/m2
Distance from hospital
Mean 23.5 miles
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III, and only 33.3% for stage IV. It is important to note that the 
cause of death was unknown and deaths include all causes for 
mortality. The mean interval from diagnosis to initial treatment 
was 47.9 days and ranged from 0 to 363 days. This interval when 
compared to survival and was noted to be statistically significant 
with patients who were still alive having a mean treatment inter-
val of 43.35 days compared to those who were dead having a mean 
interval of 64.84 days (p < 0.001).
In terms of insurance status, the longest treatment interval 
was noted in the Medicaid group with a mean treatment delay of 
78 days followed by Medicare with 54 days (Table 2). The short-
est interval was noted within the private insurance group with 
38.4 days and was found to be clinically significant (p < 0.001). 
Even when stratified by stage of disease, Medicaid and Medicare 
participants continued to have longer treatment intervals 
(Table 3).
Analysis of stage and insurance status as it pertains to survival 
demonstrated similar results (Table 4). For Stage I disease, 97.1% 
of patients with private insurance were alive compared to 95.8% 
in Medicaid and 77.1% for Medicare; 2.9% of private insurance 
patients were dead compared to 4.2 and 22.3%, respectively, for 
Medicaid and Medicare groups. Similar results were seen in Stage 
III disease with alive status for 72.7, 62.5, and 53.4% in private, 
Medicaid, and Medicare groups, respectively. In Stages II and IV, 
the private and Medicare patients had similar results in terms of 
survival. Of note, data are only available for all cause mortality.
Racial differences were noted in time to treatment intervals. 
Caucasian women had a shorter mean treatment interval 
(42.6 days) as compared to African-American women (57.3 days) 
and Hispanics (58.2 days). The shortest treatment interval time 
was noted in Asian patients with 28.6 days. These differences were 
found to be statistically significant between groups (p = 0.048) 
(Table 2).
Of note, a multivariate analysis was performed but was felt 
not to show any further informative statistics. The analysis 
shows that three effects remain in the multiple regression 
analysis – a dummy code for private insurance, a dummy code 
for Medicare, and a dummy code for African-American race. 
The two insurance codes are associated with shorter intervals, 
being African-American is associated with longer intervals. The 
interval variable was transformed to better meet assumptions of 
normal residuals (a square root transformation). These results 
are in rough agreement with the univariate results, and much of 
the difference may be accountable to collinearity between these 
measures (e.g., African-American and/or Hispanic race/ethnicity 
with use of Medicaid).
Distance from the health center and BMI were not found to be 
statistically significant for a time to treatment interval.
DiscUssiOn
In our study, patients with endometrial cancer without private 
insurance experienced significantly longer interval time to treat-
ment compared to patients with private insurance. In addition, we 
TaBle 4 | stage and insurance status as it pertains to survival.
insurance stage i stage ii stage iii stage iV
alive Dead alive Dead alive Dead alive Dead
Medicaid 23 (95.8%) 1 (4.2%) 2 (100%) 0 (0%) 5 (62.5%) 5 (37.5%) 0 (0%) 5 (100%)
Medicare 171 (77.7%) 49 (22.3%) 21 (70%) 9 (30%) 39 (53.4%) 34 (46.6%) 17 (34%) 33 (66%)
No insurance 14 (93.3%) 1 (6.7%) 1 (100%) 0 (0%)
Private 331 (97.1%) 10 (2.9%) 18 (75%) 6 (25%) 32 (72.7%) 12 (27.3%) 11 (34.4%) 21 (65.6%)
Other/unknown 11 (91.7%) 1 (8.3%) 1 (100%) 0 (0%) 0 (0%) 3 (100%) 1 (50%) 1 (50%)
Total 550 (89.9%) 62 (10.1%) 42 (73.7%) 15 (26.3) 77 (59.7%) 52 (40.3%) 30 (33.3%) 60 (66.7%)
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also found increased time to treatment interval to be associated 
with a decreased survival. Race, BMI, and distance to treatment 
center were all not significantly correlated with interval treat-
ment time. This confirms our hypothesis that socioeconomic 
status appears to negatively impact survival. This study supports 
the findings of Fedewa et  al., who also found a significantly 
improved survival in patients with private insurance (7). The 
authors speculated that patients with public insurance are less 
likely to be managed by a gynecologic oncologist. In contrast, 
a gynecologic oncologist treated all the patients in our sample. 
Our finding of increased time to treatment interval adds another 
possible explanation for both Fedewa’s findings and ours. Our 
results mirror the greater body of literature regarding insurance 
disparities in cancer mortality between the underinsured and the 
privately insured, especially with regards to breast cancer, which 
has partially been attributed to decreased cancer surveillance in 
this population (8, 9). Interestingly, in the breast cancer literature, 
this disparity in surveillance persisted even in high income adults 
without insurance (10). Our findings did correlate with the over-
all body of literature on insurance status and cancer disparities 
and wait time (7, 11–14).
Medicaid covers a disproportionately high percentage of 
minorities, specifically black patients, although whites make 
up a higher percentage of total Medicaid beneficiaries (12). 
Furthermore, many studies have found race to be a significant 
predictor of poor outcomes despite equal insurance status and 
providers (15). These studies did not assess wait time, and thus, 
perhaps race had an effect there. Increased interval wait time 
is of particular concern because patients with Medicaid and 
without insurance are more likely to present at diagnosis with 
more advanced disease, and thus, this population requires timely 
treatment (12). A perceived inability to afford medical care could 
be a major contributor to advanced presentation in the uninsured 
(8). It is unclear, however, in our study if insurance inequality 
within races accounted for significance of delay in treatment 
and decrease survival with racial groups or if race itself was a 
confounder in the delay in treatment within insurance groups.
Elit et al. reported that a delay in treatment was related to a 
decrease in overall survival for patients with uterine cancer in 
a Canadian population (11). In this study, they demonstrated 
that a wait time of more than 12 weeks had a significantly worse 
survival than patients with a wait time of 2.1–6 weeks [HR 0.79 
(95% CI 0.7–0.91)] and wait time 6–12 weeks [HR 0.8 (95% CI 
0.71–0.91)]. They postulated that the delay in treatment may be 
due to centralization of uterine cancer surgical care to gynecologic 
oncologist at teaching hospitals and less availability of operating 
room times. They also state that this increase in wait times to 
surgery may counteract any benefit seen as a result of additional 
expertise from gynecologic oncology regarding surgical staging. 
Our study demonstrates a similar correlation between survival 
and time to treatment. However, all mean delay in treatment 
time in our study was <12  weeks (84  days), with the longest 
mean delay in treatment time seen being 78.1 days (11 weeks) 
in the Medicaid group. Our study differs from the Elit study in 
that it was done in a single teaching institution with patients 
who receive surgical care from only gynecologic oncologists; 
therefore, our delay in treatment cannot be justified by less avail-
ability to operating room times or delay in referral time alone. 
Our study was also done in a different health care system where 
different insurance statuses exist and not the national health care 
system in Canada.
There were some limitations to our study. Our population was 
geographically limited to one tertiary care institution in Chicago. 
Our sample was also not nationally representative due to its 
inclusion of patients seeking care at a tertiary care institution. 
Additionally, we could not account for patient factors, including 
adherence to treatment recommendations, provider preference, 
or comorbidities, which could have limited a definitive surgical 
option. We also did not account for cancer histology, which is 
a known prognostic indicator. Information on cause of death 
was not available; hence, cancer-specific deaths could not be 
identified.
Future studies focusing on time to treatment interval, specifi-
cally at what time to treatment interval is survival affected, are 
needed. Further study of the relationship of race, socioeconomic 
status, and time to treatment will aid providers in optimizing care 
in an era of increasing restriction of resources.
In conclusion, we found a significant decrease in survival with 
longer delay between diagnosis and treatment. In addition, this 
delay was directly associated with insurance status and race in 
our population of endometrial cancer patients treated at a large, 
tertiary care institution.
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